Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 3, 2025 • 10:01 PM ET

Date/Time Source News Release
11/14/2024 04:15 PM EST PR Newswire Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/13/2024 07:00 AM EST PR Newswire Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
10/31/2024 07:30 AM EDT PR Newswire Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
10/12/2024 09:00 AM EDT PR Newswire Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
09/23/2024 07:30 AM EDT PR Newswire Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
08/19/2024 04:05 PM EDT PR Newswire Aileron Therapeutics to Present at the 8th Annual IPF Summit
08/14/2024 06:05 PM EDT PR Newswire Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
07/30/2024 08:00 AM EDT PR Newswire Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
07/01/2024 08:00 AM EDT PR Newswire Aileron Therapeutics to be Included in the Russell Microcap® Index
05/15/2024 05:13 PM EDT GlobeNewswire Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Page

Additional News

As of January 3, 2025 • 10:01 PM ET

Date/Time Source News Release
Page